Interferential Current Stim Offers New Strategies for VNS
The vagus nerve has proven to be a critical target for a number of potential new bioelectronic medicine therapies. But at the same time, this nerve has confounded research teams and startup firms pursuing indications such as heart failure and inflammatory disorders. A recent paper highlights some of the attributes of this complex nerve that make commercializing new therapies so difficult, including…
MedTech Innovator Accelerates Neurotech Commercialization
MedTech Innovator, based in Los Angeles, CA, is not venture capital firm in the strict sense. But the organization has played a significant role in helping launch a number of neurotech industry startup. MedTech Innovator bills itself as the world’s largest accelerator for medical device, digital health, and diagnostic companies. Its mission is to improve the lives of patients companies that are transforming the healthcare system.
Deciphering BCIs
The market for brain-computer interfaces continues to expand, with new players and new financing being announced almost weekly. As we report in our article on page 1 of this issue, some of the earliest competitors in this space are engaged in a race to accumulate new human participants in an effort to position themselves as a market leader, even though meaningful revenues are years away for most of these firms.
Neurotech Luminaries Look to the Future at SynBioBeta 2025
Neurotech Business Report Some of the nation’s leading neurotechnology researchers and entrepreneurs took to the stage at the recent SynBioBeta conference in San Jose, CA earlier this month to offer their views on the future of the field and its impact on society as a whole. A session called “The Neural Frontier: Pioneering Tomorrow’s Brain Technologies” was moderated , CEO of Forest Neurotech and…
Medtronic’s Diabetes Spinoff Offers Lessons for BioElectRx
Medtronic Inc., the Minneapolis, MN manufacturer of medical devices, has long been regarded as a powerhouse in neuromodulation and bioelectronic medicine. With sizable market share in product categories such as cardiac rhythm management, spinal cord stimulation, and bowel and bladder neuromodulation, the company has leveraged its engineering strength and market presence in multiple product categories.
Interferential Current Stim Offers New Strategies for VNS
The vagus nerve has proven to be a critical target for a number of potential new bioelectronic medicine therapies. But at the same time, this nerve has confounded research teams and startup firms pursuing indications such as heart failure and inflammatory disorders. A recent paper highlights some of the attributes of this complex nerve that make commercializing new therapies so difficult, including…
Draining the Brain
Many in the neurotechnology industry have come to lament some of the new policies that the incoming Trump administration has bestowed upon startups and researchers in the space. Much has made about the funding cuts, staff reductions, travel restrictions on government researchers and other clampdowns that threaten the U.S.’ preeminence in life science fields such as neurotechnology. But now a new th…
Panelists Discuss Policy Shifts at Bioelectronic Medicine Forum
Neurotech Business Report Neurotech Reports’ 2025 Bioelectronic Medicine Forum at the New York Academy of Medicine convened industry pioneers, investors, and innovators to explore the evolving landscape of bioelectronic medicine. The event illuminated both the challenges and transformative opportunities shaping this dynamic field, offering a blend of cautious optimism, regulatory insights, and groundbreaking technological advancements.
Neuromodulation Vendors Confront MRI Challenges
As spinal cord stimulation and peripheral nerve stimulation technologies continue to advance, one feature that remains a consistent focus of clinical discussion—and a key differentiator among devices—is the ability (or lack thereof) for patients with active implantable systems to safely undergo MRI scans. Even as far back as the mid-1990s, when this editor was first involved in the cochlear implant…
Discure Technologies Targets Degenerative Disc Disease
Due to the unique anatomy of our skeletal system, certain components degrade faster than others. The intervertebral disc’s inner core (nucleus pulposus) is particularly vulnerable. Lacking blood vessels, this tissue depends entirely on fluid diffusion from the disc’s outer surface for oxygen, glucose, and waste removal. This diffusion process is facilitated , hydrophilic glycosaminoglycan molecules produced .
